Videos

Drs Michael Bishop and John DiPersio comment on common challenges in measuring response in chronic GvHD and review clinical implication from the REACH3 trial.

A discussion of standard frontline treatment approaches and considerations for utilizing maintenance therapy for patients with germinal center B-cell and activated B-cell subtypes of diffuse large B-cell lymphoma.

A review of the criteria that help hematologist-oncologists appropriately manage patients with diffuse large B-cell lymphoma.

Experts in hematology/oncology review factors to consider when approaching the management of chronic graft-versus-host disease.

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, discuss possible future developments with BTKi as therapy options in B-cell lymphomas.

Drs Shadman and Cohen introduce new data concerning a third-generation BTK inhibitor, pirtobrutinib, and discuss unmet needs in the B-cell malignancy landscape.

Jason Westin, MD, discusses the future of diffuse large B-cell lymphoma treatment.

Guiseppe Curigliano, MD, discusses the rationale behind a subgroup HER2CLIMB study, which evaluated the efficacy and safety of tucatinib in combination with trastuzumab and capecitabine in pretreated HER2-positive breast cancer patients with and without brain metastases compared with placebo.

Irene Ghobrial, MD discusses multiple trials and their significance for treating patients with smoldering multiple myeloma and newly diagnosed multiple myeloma.

Neeraj Agarwal, MD, discusses the PSA response rate and adherence rate of a real-world study of apalutamide in patients with prostate cancer across 63 United States urology practices.

Erika P. Hamilton, MD, discusses unmet needs in treatment options for platinum-resistant ovarian cancer due to the challenges of screening, and what treatment options may become viable in the future.

John DiPersio, MD, PhD, and Michael Bishop, MD, discuss third-line treatment options for patients with acute and steroid-refractory GVHD.

John DiPersio, MD, PhD, shares his thoughts on approaching initial therapy for chronic GVHD and early intervention with JAK inhibitors.

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, share their preferences regarding BTK-targeted treatment in B-cell malignancies.

Two experts discuss use of ibrutinib and zanubrutinib and data from the ALPINE and ELEVATE-RR trials.

Michael Wang, MD, discusses the real-world efficacy of brexucabtagene autoleucel, the first chimeric antigen receptor T-cell therapy for the treatment of mantle cell lymphoma.

Scott T. Tagawa, MD, FACP, shares clinical pearls and advice for the management of mCRPC.

An expert in prostate cancer comments on emerging agents and combinations in the pipeline for the treatment of mCRPC.

Scott T. Tagawa, MD, FACP, shares his thoughts on remaining questions for imaging and PSMA-targeted therapy for mCRPC.

Dr Scott T. Tagawa discusses common adverse events associated with 177Lu-PSMA-617 in patients with mCRPC and how to appropriately manage them.

A prostate cancer expert considers clinical implications from the phase 3 VISION study, including the potential role of 177Lu-PSMA-617 therapy for patients with mCRPC.

Scott T. Tagawa, MD, FACP, reviews the phase 3 VISION trial evaluating the use of 177Lu-PSMA-617 therapy in patients with mCRPC.

An expert in prostate cancer reviews available options for the treatment of mCRPC and considerations for selecting the optimal therapy.

Dr Scott T. Tagawa reviews traditional imaging techniques and advances in imaging used in clinical practice for prostate cancer.

Scott T. Tagawa, MD, FACP, discusses the heterogeneity and features of prostate cancer and provides insight on biomarker testing.

Shaji Kumar, MD, a hematologist at the Mayo Clinic and chair of the Plasma Cell Disorders Scientific Committee at the American Society of Hematology, discuses the standard of care in newly diagnosed myeloma.

Tomasz M. Beer, MD, FACP, shares unmet needs and clinical pearls for the management of patients with mCRPC.

An expert in prostate cancer comments on selecting the optimal systemic therapy for metastatic castration-resistant prostate cancer (mCRPC) treatment.

Tomasz M. Beer, MD, FACP, shares his personal experience using darolutamide for patients with CRPC and discusses his approach to patient selection of the drug in the metastatic setting.

Sarah P. Psutka, MD, discusses the efficacy of the combination of immune checkpoint inhibitor therapy plus tyrosine kinase inhibitor for the treatment of metastatic renal cell carcinoma.